Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey
The Omicron variant of SARS-CoV-2 has been characterized by high levels of immune evasion [1]. The most recently emerged subvariants, BQ.1.1 and XBB, have been shown to effectively evade immunity generated by vaccines, including bivalent formulations designed specifically to target Omicron BA.5 [1-3]. In addition to diminishing vaccine effectiveness, the continued evolution of Omicron variants may limit the utility of available treatment options such as Nirmatrelvir/ritonavir or molnupiravir [4, 5]. (Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - December 7, 2023 Category: Infectious Diseases Authors: Juan P. Aguilar Ticona, Meng Xiao, Dan Li, Nivison Nery, Matt Hitchings, Emilia M. M. Andrade Belitardo, Mariam O. Fofana, Renato Victoriano, Jaqueline S. Cruz, Laise Eduarda Paix ão de Moraes, Icaro Morais Strobel, Jessica Jesus Silva, Ananias Sena do A Source Type: research
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
CONCLUSIONS: This is the most comprehensive network meta-analysis integrating RCTs and real-world data. In our indirect comparison, remdesivir was associated with the highest efficacy in preventing hospitalization among high risk symptomatic COVID-19 outpatients, compared to nirmatrelvir/ritonavir and molnupiravir. This finding supports current guidelines, and may have importance when deciding which antiviral to use, together with other important factors.PMID:38056602 | DOI:10.1016/j.antiviral.2023.105768 (Source: Antiviral Research)
Source: Antiviral Research - December 6, 2023 Category: Virology Authors: Meital Zur Thalia Peselev Stav Yanko Victoria Rotshild Ilan Matok Source Type: research
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
CONCLUSIONS: This is the most comprehensive network meta-analysis integrating RCTs and real-world data. In our indirect comparison, remdesivir was associated with the highest efficacy in preventing hospitalization among high risk symptomatic COVID-19 outpatients, compared to nirmatrelvir/ritonavir and molnupiravir. This finding supports current guidelines, and may have importance when deciding which antiviral to use, together with other important factors.PMID:38056602 | DOI:10.1016/j.antiviral.2023.105768 (Source: Antiviral Research)
Source: Antiviral Research - December 6, 2023 Category: Virology Authors: Meital Zur Thalia Peselev Stav Yanko Victoria Rotshild Ilan Matok Source Type: research
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
CONCLUSIONS: This is the most comprehensive network meta-analysis integrating RCTs and real-world data. In our indirect comparison, remdesivir was associated with the highest efficacy in preventing hospitalization among high risk symptomatic COVID-19 outpatients, compared to nirmatrelvir/ritonavir and molnupiravir. This finding supports current guidelines, and may have importance when deciding which antiviral to use, together with other important factors.PMID:38056602 | DOI:10.1016/j.antiviral.2023.105768 (Source: Antiviral Research)
Source: Antiviral Research - December 6, 2023 Category: Virology Authors: Meital Zur Thalia Peselev Stav Yanko Victoria Rotshild Ilan Matok Source Type: research
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
Conclusion: We showed NR therapy to be associated with a favorable outcome and an acceptable safety profile in an immunosuppressed population with RD during the Omicron surge. Early use of NR (within 5 days of symptom onset) could improve the prognosis of patients. NR administration for symptoms and confirmed SARS-CoV-2 infection after >5 days may also mitigate progression to severe disease and is a viable strategy. Our results highlight the importance of early utilization and/or NR indication, which may yield clinical advantages for patients with RD infected with SARS-CoV-2. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - December 6, 2023 Category: Drugs & Pharmacology Source Type: research
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Antiviral Res. 2023 Nov 30:105766. doi: 10.1016/j.antiviral.2023.105766. Online ahead of print.ABSTRACTCoronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available and their efficacy in randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting the need for more potent treatments. We previously showed that cobicistat, a clinically approved inhibitor of Cytochrome P450-3A (CYP3A), has direct antiviral activity against early cir...
Source: Antiviral Research - December 2, 2023 Category: Virology Authors: Lara Gallucci James Bazire Andrew D Davidson Iart Luca Shytaj Source Type: research
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Antiviral Res. 2023 Nov 30:105766. doi: 10.1016/j.antiviral.2023.105766. Online ahead of print.ABSTRACTCoronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available and their efficacy in randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting the need for more potent treatments. We previously showed that cobicistat, a clinically approved inhibitor of Cytochrome P450-3A (CYP3A), has direct antiviral activity against early cir...
Source: Antiviral Research - December 2, 2023 Category: Virology Authors: Lara Gallucci James Bazire Andrew D Davidson Iart Luca Shytaj Source Type: research
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Antiviral Res. 2023 Nov 30;221:105766. doi: 10.1016/j.antiviral.2023.105766. Online ahead of print.ABSTRACTCoronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available and their efficacy in randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting the need for more potent treatments. We previously showed that cobicistat, a clinically approved inhibitor of Cytochrome P450-3A (CYP3A), has direct antiviral activity against early...
Source: Antiviral Research - December 2, 2023 Category: Virology Authors: Lara Gallucci James Bazire Andrew D Davidson Iart Luca Shytaj Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Emerg Infect Dis. 2023 Dec 1;30(1). doi: 10.3201/eid3001.230414. Online ahead of print.ABSTRACTWe compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed with...
Source: Emerging Infectious Diseases - December 1, 2023 Category: Infectious Diseases Authors: Yue Yat Harrison Cheung Eric Ho Yin Lau Guosheng Yin Yun Lin Benjamin J Cowling Kwok Fai Lam Source Type: research
Disparate viral pandemics from COVID19 to monkeypox and beyond: a simple, effective and universal therapeutic approach hiding in plain sight
The field of antiviral therapeutics is fixated on COVID19 and rightly so as the fatalities at the height of the pandemic in the United States were almost 1,000,000 in a twelve month period spanning parts of 2020/2021. A coronavirus called SARS–CoV2 is the causative virus. Development of a vaccine through molecular biology approaches with mRNA as the inducer of virus spike protein has played a major role in driving down mortality and morbidity. Antivirals have been of marginal value in established infections at the level of hospitalization. Thus, the current focus is on early symptomatic infection of about the first five...
Source: Frontiers in Immunology - December 1, 2023 Category: Allergy & Immunology Source Type: research
